{"nctId":"NCT01857583","briefTitle":"Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs","startDateStruct":{"date":"2012-03"},"conditions":["Venous Thromboembolism"],"count":80,"armGroups":[{"label":"SRI 15mg (15 mL/min ≤ CLCR < 20mL/min)","type":"EXPERIMENTAL","interventionNames":["Drug: 15mg DU-176b"]},{"label":"MiRI 30mg (50 mL/min ≤ CLCR ≤ 80mL/min)","type":"EXPERIMENTAL","interventionNames":["Drug: 30mg DU-176b"]},{"label":"Fondaparinux (20 mL/min ≤ CLCR < 30mL/min)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Fondaparinux"]},{"label":"SRI 15mg (20 mL/min ≤ CLCR < 30mL/min)","type":"EXPERIMENTAL","interventionNames":["Drug: 15mg DU-176b"]}],"interventions":[{"name":"15mg DU-176b","otherNames":["edoxaban"]},{"name":"30mg DU-176b","otherNames":["edoxaban"]},{"name":"Fondaparinux","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with SRI or MiRI undergoing orthopedic surgery of the lower limbs\n\nExclusion Criteria:\n\n* Patients who are on hemodialysis or are scheduled to undergo hemodialysis during the study period\n* Patients who are at a significantly high risk for bleeding or thromboembolism\n* Patients who are receiving another antithrombotic therapy and are unable to suspend the therapy\n* Patients who have evidence of hepatic function test abnormalities","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Any Adjudicated Bleeding Events","description":"Incidence of any adjudicated bleeding events (including major bleeding, clinically relevant non-major bleeding, and minor bleeding).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"14.3","spread":null},{"groupId":"OG002","value":"22.7","spread":null},{"groupId":"OG003","value":"40.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Adverse Events","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"PRIMARY","title":"Incidence of Adverse Drug Reactions","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"PRIMARY","title":"Plasma Concentration of DU-176b","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"PRIMARY","title":"Plasma Concentration of D21-2393","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Incidence of Adjudicated Thromboembolic Events","description":"Incidence of adjudicated thromboembolic events (symptomatic Deep Vein Thrombosis (DVT), symptomatic Pulmonary Thromboembolism (PTE), Venous Thromboembolism (VTE) related deaths).","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":30},"commonTop":["Gamma-glutamyltransferase increased","Haemorrhage subcutaneous","cystitis","Blood urine present","Aspartate aminotransferase increased"]}}}